Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Bare metal stents provide a safer choice

While drug-eluting stents are effective in keeping open diseased heart arteries, they should not be used for patients who need to have non-cardiac surgery a short time after an interventional heart procedure.

15 May 2007

Stent thrombosis

Over the last year, it's been rare to utter the word "stent" without at least thinking "thrombosis," an uncommon but serious complication that's been on the minds of interventional cardiologists and patients alike.

11 May 2007

Efforts to standardize heart care are working

People who suffer a heart attack or severe chest pain today are much less likely to die, or to experience long-lasting effects, than their counterparts even a few years ago, according to a new international study in the May 3 issue of the Journal of the American Medical Association.

2 May 2007

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.

20 Apr 2007

Long-term safety of drug-eluting stents in off-label use

Research presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent - a dangerous complication - and adherence and responsiveness to anti-clotting medication.

3 Apr 2007

Advances in clinical cardiology

Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.

3 Apr 2007

Adding estradiol to a polymer-free rapamycin-eluting stent is not associated with any measurable benefit

Patients admitted to the hospital with acute coronary syndromes (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention (PCI), during which a stent is inserted into an occluded or narrowed coronary artery to restore blood flow to and from the heart.

2 Apr 2007

Plavix appears to be safe during and after heart bypass

Heart surgeons don't have to choose between taking a coronary-bypass patient off the popular anti-clotting drug clopidogrel (Plavix) after off-pump heart bypass surgery or having the patient bleed excessively in the days following surgery, according to a new study by researchers at Jefferson Medical College.

28 Mar 2007

Researchers create roadmap to integrin activation

Calling it an important technical advance in the study of the complex receptors and pathways of the body's cellular system, researchers at the University of California, San Diego (UCSD) School of Medicine have reconstructed the signaling pathways that impact activation of a receptor that is critical to the control of bleeding and to the thrombosis that occurs in heart attacks and strokes.

18 Sep 2006

How effective is continued Plavix therapy in patients undergoing a repeat stent procedure?

Clopidogrel (Plavix) is used worldwide in millions of patients after placement of coronary artery stents. Sales of the drug exceed 5 billion US dollars.

5 Sep 2006

FDA approves Plavix for STEMI heart attacks

The Food and Drug Administration (FDA) today approved the use of Plavix (clopidogrel bisulfate) for patients who have had a type of heart attack called acute ST-segment elevation myocardial infarction (STEMI), who are not going to have coronary artery repair (angioplasty).

17 Aug 2006

Sanofi-aventis and Bristol-Myers Squibb agree to settle patent dispute with Apotex

Sanofi-aventis and Bristol-Myers Squibb have announced that they have reached an agreement subject to certain conditions with Apotex to settle the patent infringement lawsuit pending between the parties in the U.S. District Court for the Southern District of New York.

21 Mar 2006

Researchers evaluate efficacy, safety of anti-clotting drugs

Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.

15 Mar 2006

Clopidogrel reduces risk of adverse events for patients with acute coronary syndromes undergoing balloon angioplasty

Patients with acute coronary syndromes who were pre-treated with the anti-platelet agent clopidogrel before undergoing a procedure such as balloon angioplasty or stent placement had a reduced risk of adverse events if they received the anti-clotting drug abciximab

14 Mar 2006

New device for fixing holes in hearts of young stroke patients

As many as one in four adults is walking around with a "hole" between the upper chambers of the heart. Most of them will never know it.

14 Mar 2006

Physicians slow to prescribe newer heart drugs

An analysis of the treatment received by more than 100,000 heart patients has shown that physicians' prescription practices for drugs proven effective for treating heart disease has shown steady improvement over the past three years, cardiologists at the Duke Clinical Research Institute (DCRI) have concluded.

7 Dec 2005

Lack of aggressive treatment for clogged leg blood vessels means missed heart attack prevention opportunity

Despite the fact that clogged arteries in the legs usually mean clogged arteries near the heart, doctors often fail to give heart-protecting drugs to people with severe leg blood vessel blockages, a new University of Michigan-led study finds.

15 Nov 2005

Real-world treatment of patients with acute coronary syndromes

A review of more than 56,000 cases of acute coronary syndromes reveals that older patients are less likely to receive treatment recommended by guidelines, even though they benefit as much or more than younger patients when the recommended treatment is provided, according to a new study in the Oct. 18, 2005, issue of the Journal of the American College of Cardiology.

11 Oct 2005

Part of largest randomised international trial program ever conducted in atrial fibrillation (AF) discontinued

Study treatments for the ACTIVE W trial of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation (OAC) over antiplatelet therapy (clopidogrel plus aspirin).

6 Sep 2005

Use of the antiplatelet drug clopidogrel before a coronary angioplasty reduces risk of cardiovascular death

Use of the antiplatelet drug clopidogrel before a coronary angioplasty reduced the risk of cardiovascular death, heart attack or stroke within 30 days following the procedure, according to an article in the September 14 issue of JAMA: The Journal of the American Medical Association.

5 Sep 2005